AstraZeneca awaits decision in US Crestor patent case
08 March 2010
Nancy Faigen
AstraZeneca has a lot riding on the outcome of US patent litigation relating to its cholesterol therapy, Crestor (rosuvastatin). It failed last December in its attempt to gain summary judgement on allegations of inequitable conduct in the obtainment of the active ingredient patent ('314), and as a...
Please Login to read the full article.
08 March 2010
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Obama wants one-stop shop for patents, trade & small biz aid
- White House acknowledges Lilly chief's role in patent reform victory
- Mylan loses bid to have US Teva patent infringement suit on Copaxone tossed out
- Supreme Court weighs patent validity standard of proof in Microsoft v. i4i
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
